Cesar Cardenas retweetledi

Capivasertib is now approved in 🇪🇺 for the treatment of advanced, HR+/HER2- breast cancer. Important to ensure access to NGS/ctDNA for European patients in order to identify PIK3CA/AKT/PTEN alterations. astrazeneca.com/media-centre/p…

English













